Key Highlights

  • BFLY shares are trading up 10.14% to $7.34, against a prior close of $6.66.
  • Third-quarter results are due before the market opens on Thursday, October 29.
  • Revenue is expected near $28.4 million, about 32% above the $21.49 million reported a year earlier.
  • Second-quarter revenue of $32.61 million topped the $29.16 million estimate.
  • Options imply a next-day move of about 18.96%, versus an average one-day move of 25.06%.

Pre-Earnings Positioning Lifts the Handheld Ultrasound Maker

Butterfly Network (NYSE:BFLY) shares are trading up 10.14% to $7.34 as investors position ahead of its third-quarter earnings report, due before the market opens on Thursday. The company also announced it will present at the UBS Global Healthcare Conference on November 10. No new fundamental news was announced today beyond the conference notice, so the move may reflect pre-earnings positioning and the stock's high beta of about 2.0.

Shares opened at $6.76, and the 52-week range runs from $1.90 to $10.21. The stock sits below its 50-day average near $8.21 after a volatile run, and it is outpacing a mostly flat healthcare sector as defensive rotation favors the group.

Analysts Expect 32% Revenue Growth and a Narrow Loss

Estimates call for revenue of about $28.0 million to $28.4 million, around 32% growth from $21.49 million a year earlier, and a loss of roughly $0.03 to $0.04 per share. Last quarter, Butterfly reported a loss of $0.01 per share against $0.04 expected, on revenue of $32.61 million versus $29.16 million expected. The company has beaten EPS estimates in at least six of the last seven quarters, based on the data provided.

Recent initiations from Canaccord, Needham and Evercore carry Buy or Outperform ratings with price targets between $10 and $15.

Compass AI, HomeCare and Embedded Chips Broaden the Platform

Butterfly, based in Burlington, Massachusetts, develops handheld, single-probe, whole-body ultrasound systems built on its proprietary Ultrasound-on-Chip technology. Its portfolio includes the Butterfly iQ+ and iQ3 probes and cloud software such as Compass AI, ScanLab and teleguidance tools, sold through a direct sales force, distributors and e-commerce channels.

The company is expanding beyond point-of-care ultrasound into HomeCare and Butterfly Embedded semiconductor co-development partnerships, including one with Midjourney. First-quarter 2026 revenue was $26.5 million, up 25%, and the market cap is $1.95 billion with a loss of $0.24 per share. A long-term ultrasound education alliance with the Edward Via College of Osteopathic Medicine was announced October 13, and an insider share sale was reported October 8.

Cash Runway and Dilution Risk Top the Watch List

Investors will watch revenue growth, margin and net loss trends, cash runway and dilution risk, alongside progress on Compass AI, Butterfly Garden apps and HomeCare pilots. Second-quarter net margin improved to about negative 39.6%. The implied move of about 18.96% shows the market expects a large reaction.